CLL is associated with an increased IDO1 expression and activity, but its pharmaceutical inhibition is not sufficient to control leukemia development in a mouse model of CLL, suggesting compensatory mechanisms, such as that of IL4I1, in place that maintain immunosuppression. Here, IDO1 is linked to leukemia.